The 5-year data strengthens the case for TransCon PTH as a long-term treatment for hypoparathyroidism, potentially expanding its addressable market and supporting pricing negotiations. Traders should watch for upcoming regulatory milestones (e.g., FDA decision or label expansion) and commercial launch updates. The high completion rate and sustained efficacy reduce clinical risk.
ASND drugs
ASND drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 12 $218.06entry
- T+1 · 5mo ago +2.40%α +0.64% · $223.29
- T+5 · 5mo ago +5.86%α +5.18% · $230.83
- T+20 · 4mo ago +24.03%α +22.25% · $270.45
- T+60 · 2mo ago +23.86%α +20.60% · $270.09
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ascendis Pharma announced 5-year (Week 266) data from its Phase 2 PaTH Forward Trial for TransCon PTH in hypoparathyroidism, showing sustained efficacy and safety. Key results include 82% responder rate on the multi-component endpoint, normalized serum calcium in 88% of patients, independence from active vitamin D in 96%, and maintained kidney function improvements. The data reinforces the drug's long-term profile, which is positive for the ongoing regulatory and commercial narrative.
Key Facts
- 82% of patients met the multi-component endpoint (normal serum calcium, no active vitamin D, <600 mg/day calcium) at Week 266.
- 88% of patients had normal albumin-adjusted serum calcium (mean 9.0 mg/dL).
- 96% achieved independence from active vitamin D; 95% from therapeutic calcium doses.
- Mean eGFR increased by 9.4 mL/min/1.73 m² from baseline to Week 266, sustained over 5 years.
- 95% (56/59) of patients completed the 5-year trial; no discontinuations related to study drug.
- No new safety signals; one patient had transient, non-neutralizing anti-PTH antibodies without impact.
Financial Impact
No financial figures provided; the data supports the commercial potential of TransCon PTH in hypoparathyroidism, a condition with limited treatment options.
Risk Factors
- Regulatory delays or additional trial requirements for label expansion.
- Competition from other therapies (e.g., Eneboparatide, AZP-3601) in development.
- Commercial execution risk: adoption by endocrinologists and payer coverage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-268415 |
| Document: 0001193125-26-268415-index-headers.html | 0001193125-26-268415 |
| Document: 0001193125-26-268415-index.html | 0001193125-26-268415 |
| Document: 0001193125-26-268415.txt | 0001193125-26-268415 |
Track record
41 reports on ASND
13 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
- Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
- Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers